FUNglucan: Investigating Effects in Intestinal Permeability of Rich in Beta-glucans Pleurotus Eryngii Mushrooms Fermentation Supernatants: an Ex-vivo Study
The aim of the present study was to investigate the ability of Pleurotus eryngii mushrooms fermentation products (FS) to counteract induced intestinal hyperpermeability in human colonic tissues in an ex vivo system.
|Condition or Disease||Intervention/Treatment||Phase|
Collection of colon biopsies through sigmoidoscopy procedure will take place and the collected biopsies will be mounted in Ussing Chambers. Already collected fermentation supernatants will be added to the mucosal side of the biopsy together with a stressor and two permeability markers, in order to investigate the effects of the fibre fractions on both paracellular and transcellular permeability.
Arms and Interventions
|Experimental: Gut barrier function treatments
Stressor, fibre, combination of treatments.
Other: Fermented product of Pleurotus eryngii mushroom
I Stimulation of human colonic biopsies with the fermented product of Pleurotus eryngii mushroom
Primary Outcome Measures
- Change from baseline of barrier function (paracellular permeability) after 90 minutes of ex vivo stimulation of the colonic biopsies. [Barrier function will be measured at baseline and after 90 minutes of ex vivo stimulation of the colonic biopsies.]
Barrier function (paracellular permeability) will be evaluated with the use of marker related this permeability, through immunofluoresence.
- Change from baseline of barrier function (transcellular permeability) after 90 minutes of ex vivo stimulation of the colonic biopsies. [Barrier function will be measured at baseline and after 90 minutes of ex vivo stimulation of the colonic biopsies.]
Barrier function (transcellular permeability) will be evaluated with the use of marker related to this permeability, through ELISA tecnhique.
Signed consent prior to any study related procedures
Age 18-65 years
Willing to abstain from regular consumption of prebiotics/probiotics products or medication known to alter gastrointestinal functions at least 4 weeks prior to the study visits
Previous complicated gastrointestinal surgery
Presence of gastrointestinal disorder or any disorder which the principal investigator considers to affect the results of the study
Current diagnosis of psychiatric disease
Current and past diagnosis inflammatory gastrointestinal disease (e.g. Irritable Bowel Disease)
Systemic use of antibiotics or steroids medications in the last 3 months
Frequent use of NSAID (Non Steroidal Anti Inflammatory Drugs) the last 2 months prior to study visits
Regular consumption of prebiotic/probiotic products for the past 4 weeks
Abuse of alcohol or drugs
Frequent use of laxatives, anti-diarrheal, anti-cholinergic within last 12 weeks prior to study visits
Pregnancy and breast-feeding
Contacts and Locations
|1||Campus USÖ||Örebro||Sweden||703 62|
Sponsors and Collaborators
- Örebro University, Sweden
- Harokopio University
- Agricultural University of Athens
- National Hellenic Research Foundation
- Principal Investigator: Ignacio Rangel, As.Professor, Örebro University, School of Medical Sciences, Sweden
Study Documents (Full-Text)
- Research center website
- Description Project's official website
- Description Project's official facebook website
- Description Project's official instagram website